NCT00144794招募中不适用
Mucopolysaccharidosis I (MPS I) Registry
Genzyme, a Sanofi Company180 个研究点 分布在 2 个国家目标入组 1,500 人开始时间: 2003年11月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,500
- 试验地点
- 180
- 主要终点
- To evaluate the long-term effectiveness of Aldurazyme
研究概览
简要总结
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
- To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase)
- To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I
- To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care
详细描述
The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact:
- In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com
- In Europe - +31-35-699-1232, europe@mpsiregistry.com
- In Latin America - +617-591-5500, help@mpsiregistry.com
- In North America - +617-591-5500, help@mpsiregistry.com
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients with a confirmed diagnosis of MPS I are eligible for inclusion. Confirmed diagnosis is defined as: A. documented biochemical evidence of a deficiency in alpha (a)-L-iduronidase enzyme activity and/or B. mutation(s) in the gene coding for a-L-iduronidase, or measurable clinical signs and symptoms of MPS I
- •For all patients there should be a completed patient authorization form
排除标准
- •No exclusion criteria for participation in the MPS I Registry. NOTE: Registry participation does not exclude participation in other clinical studies.
结局指标
主要结局
To evaluate the long-term effectiveness of Aldurazyme
时间窗: Approximately 17 Years
次要结局
未报告次要终点
研究者
研究点 (180)
Loading locations...
相似试验
招募中
不适用
Mucopolysaccharidosis VII Disease Monitoring ProgramMucopolysaccharidosis VIIMPS 7Sly SyndromeMPS VIINCT03604835Ultragenyx Pharmaceutical Inc50
已完成
2 期
A Study in MPS VI to Assess Safety and Efficacy of OdiparcilMucopolysaccharidosis VINCT03370653Inventiva Pharma20
已完成
不适用
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip DiseaseMucopolysaccharidosis IV AMucopolysaccharidosis VINCT01707433Children's Hospitals and Clinics of Minnesota22
Unknown
不适用
Natural History Observational Study of MPS IIIa in SMCSanfilippo Syndrome ANCT04918641Samsung Medical Center25
已完成
不适用
Core Outcome Set for Head, Neck and Respiratory Disease in Mucopolysaccharidosis IIMucopolysaccharidosis Type IINCT06022380Manchester University NHS Foundation Trust46